Alnylam Pharmace. buy The Goldman Sachs Group, Inc.
Summary
This prediction is currently active. With a performance of 3.96%, the BUY prediction by The_Goldman_Sachs_Gr for Alnylam Pharmace. is trending in the right direction. This prediction currently runs until 16.08.25. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Alnylam Pharmace. | 2.929% | 2.929% |
iShares Core DAX® | 1.164% | 1.549% |
iShares Nasdaq 100 | 0.118% | 0.969% |
iShares Nikkei 225® | 1.124% | -1.120% |
iShares S&P 500 | 0.479% | 1.068% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Alnylam Pharmace. diskutieren